🤖 🧠 Thibault GEOUI 🧬 💊

Eroom's Law dictates that drug discovery become slower and more expensive over time, creating a scenario where spending increases but new approvals do not. This has held true since 1940. However, a 2023 update suggests that spending and productivity have begun to stabilise, with current estimates hovering at just under one drug per $1bn in spending. We'll need to wait a bit longer to see if this trend will continue, then the next step would be to explore how/if we can reduce spending. #EroomsLaw #DrugDiscovery #Pharma #Productivity

4

1 Kommentar

The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward: The full Nature study article (link in comments) is def worth a read but here is the summary>> BACKGROUND 🔘The 2019 German Digital Healthcare Act established the Digital Health Application program (DiGA) , creating a framework for integrating Digital Therapeutics (DTx) into the healthcare system 🔘 Since its inception, over 374,000 DiGA prescriptions have been issued, highlighting the program’s integration into the healthcare system 🔘 DiGA products undergo a structured assessment covering technical and evidence-based criteria, and are eligible for provisional listing to gather further evidence. 🔘 As of January 2024, 53 DiGAs are listed, with 29 permanent and 24 provisional 🔘 The majority of DiGAs address mental health, musculoskeletal, neurological, and endocrinological conditions. 🔘 Most DiGA users are female, reflecting women's higher participation in DTx trials and medical care in general 🔘 Most permanently listed DiGAs are prescribed for 90 days, aligning with the quarterly billing cycle. After this period, four DiGAs offer discounted subsequent prescriptions. The initial mean cost is €465.42, with final negotiated prices averaging €220.79. CRITICISMS & CHALLENGES 🔘 Public insurance companies have criticized the perceived low effectiveness and insufficient evidence for some DiGAs. 🔘 Manufacturers report delays in patient access to prescribed DiGAs, averaging 13 days but future changes will mandate faster access (within two days) and also better integration with electronic health records 🔘 Current pricing models do not reflect treatment success, but starting in 2026, 20% of a DiGA’s reimbursement price will be linked to success measures, promoting value-based pricing 🔘 Despite progress, challenges persist in ongoing evidence generation and achieving international standardization of DTx products 🔘 The DiGA program while not perfect allows broad access to DTx in Germany and serves as a model for other countries, with similar initiatives being developed in France and Belgium. 🗺️ Chart below shows current DiGA pathway and upcoming regulatory changes 👇Link to study article in comments below #DigitalHealth #DTx

58

5 Kommentare

🌟 𝐇𝐨𝐰 𝐓𝐡𝐞 𝐀𝐯𝐞𝐭𝐢𝐱 𝐖𝐨𝐫𝐤-𝐋𝐢𝐟𝐞 𝐁𝐚𝐥𝐚𝐧𝐜𝐞 𝐇𝐚𝐬 𝐂𝐡𝐚𝐧𝐠𝐞𝐝 𝐌𝐲 𝐋𝐢𝐟𝐞 🌟 I am astounded by the improvements in my life since joining Avetix Group, and here's why: 📚 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡: The culture at Avetix has motivated me to invest in myself—reading more and integrating personal goals into my work OKRs. It's remarkable how much the people around you can influence your growth! 🕒 𝐅𝐥𝐞𝐱𝐢𝐛𝐢𝐥𝐢𝐭𝐲: The flexible hours at Avetix have been a game-changer, allowing me to commit to regular gym sessions, which has been massive for my mental and physical health. Escaping the rigid, school-like start, finish, and lunch times, and working for a company that trusts me to manage my time effectively is truly liberating. 🌱 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐒𝐭𝐫𝐞𝐬𝐬: The overwhelming stress I once felt is gone, replaced by genuine excitement every time I step into the office. This positive change has significantly upped my performance to new heights I didn't know I could reach! 🔋 𝐄𝐥𝐞𝐜𝐭𝐫𝐢𝐜 𝐀𝐭𝐦𝐨𝐬𝐩𝐡𝐞𝐫𝐞: There’s an electric buzz around the office! We're all on this incredible journey together, sharing long-term goals that we are genuinely invested in! Not many companies can say that 😉. 𝐀𝐯𝐞𝐭𝐢𝐱 𝐡𝐚𝐬 𝐫𝐞𝐩𝐥𝐚𝐜𝐞𝐝 𝐜𝐨𝐧𝐟𝐮𝐬𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐩𝐮𝐫𝐩𝐨𝐬𝐞, 𝐬𝐭𝐫𝐞𝐬𝐬 𝐰𝐢𝐭𝐡 𝐞𝐱𝐜𝐢𝐭𝐞𝐦𝐞𝐧𝐭, 𝐚𝐧𝐝 𝐢𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐜𝐚𝐦𝐚𝐫𝐚𝐝𝐞𝐫𝐢𝐞. Walt Disney said, “𝐀𝐥𝐥 𝐨𝐮𝐫 𝐝𝐫𝐞𝐚𝐦𝐬 𝐜𝐚𝐧 𝐜𝐨𝐦𝐞 𝐭𝐫𝐮𝐞 𝐢𝐟 𝐰𝐞 𝐡𝐚𝐯𝐞 𝐭𝐡𝐞 𝐜𝐨𝐮𝐫𝐚𝐠𝐞 𝐭𝐨 𝐩𝐮𝐫𝐬𝐮𝐞 𝐭𝐡𝐞𝐦.” At Avetix, we live that belief every day.

10

OpenAI releases #o1. The demo showcases a step as ‘thinking’ when, in fact, it's running scenarios. Simplifying complex ideas can sometimes lead to a false sense of precision. The same applies to #autopilot. That aside, a giant step in improving coding productivity. Here is an great take from Lex Fridman

12

To train NPCs (non-playable characters) to behave in a more human way is the best way to explain how AI is used in gaming. Think about NPCs moving to stand under a tree, or pull out an umbrella when it starts raining. They can also react differently depending on the choices of a character with many examples. This will definitely change the gaming industry and make it much more realistic. Interesting.

2

Thanks for the wonderful feedback following our oral presentation at the European Society for Gene and Cell Therapy, Rome 2024... EXG202: Next Generation Intravitreal Gene Therapy for Patients with Age-Related Macular Degeneration and Neovascular Eye Diseases. I am delighted to share the slides here. In summary, the success of rAAV-based gene therapy for most ocular diseases depends on efficient delivery of the vector to the photoreceptors (PR), and/or retinal pigment Epithelium (RPE). While subretinal administration provides the most direct access to the PR and RPE, it is more invasive, with a risk of damage to the retinal tissue. Intravitreal (IVT) injection is a safe, non-surgical procedure and has been widely used for delivery of protein therapeutics to treat common retinal diseases. EXG202, is a novel gene therapy that is packaged in a proprietary capsid, which targets deep retinal cells more specifically, enabling delivery via Intravitreal Injection, rather than the more invasive subretinal injection. Our unique approach is built on targeting multiple pathways involved in neovascular disease and packaging the payload in a proprietary capsid that targets deep retinal cells more specifically than other known capsids. We believe this will result in a "Best-In-Class" treatment for Age-Related Macular Degeneration, Diabetic Macular Edema and other common ocular diseases. We are currently conducting clinical trials in USA and China and hope to share further data in the coming months. EXG202: Highlights from ESGCT Oral Presentation (slides attached)... 1.Novel gene therapy targeting the widest range of signaling pathways involved in neovascular disease: VEG-F (A/B/C/D), PIG, Ang-2. 2. Proprietary IVT capsid increases retinal transduction efficiency 3 to 5-fold vs AAV2.7m8 in Non-Human Primates. 3. Clear dose response in inhibiting retinal detachment in the severe NV Opsin/VEGF mouse model via IVT delivery, representing a 10-fold improvement in potency vs the same payload delivered via subretinal injection. 4. Excellent safety profile in both Cyno and Rhesus monkeys. 5. Good manufacturability in suspension cultured HEK293 cells. Over 200 Million people worldwide are living with Age-Related Macular Degeneration, Diabetic Macular Edema and other Neovascular Eye Diseases. Exegenesis Bio is committed to developing new treatments that address these diseases more effectively by targeting multiple disease pathways and improving delivery to the eye. Congratulations to the Exegenesis Bio team for continuing to deliver amazing results across our portfolio - ahead of plan! Please review the attached slides for more detailed information about EXG202 and our Ocular Disease programs - and please reach out if you would like to discuss the data. #gentherapy # celltherapy #AAV #AMD #eyediseases #diabetes #eye #capsid #ophthalmology #blindness #sight #vision #CGT #treatment #injection #intravitreal #subretinal #R&D #innovation #science #patients

13

7 Kommentare

“Prompt engineering or AI therapy? Also jobs that pay $400K now” It was a packed house at the BIO IT world opening plenary session with Texas Advanced Computing Center’s Dr. Dan Stanzione. Few core themes of this talk:  ➡ AI hardware will dominate. The market for AI driven hardware will be $300B in 2025 ➡ AI is a young and fast changing field. You can’t spell linear regression without AI. (lol) ➡ HPC, AI hardware, and sustainability. We are using A LOT of power to do this stuff. GPUs are easy, it’s the transformers that are hard (and expensive) ➡ AI will be incredibly useful, but likely not ubiquitous. AI will be useful as assistants to synthesize, distill, and extract knowledge. I particularly appreciated the #precisionmedicine prompt examples that could be used to extract knowledge from thousands if not millions of research papers: How well studied and role? Is this essential for survival? Any drugs targeting this protein? What are the impacts of mutation? What other proteins does it interact with? Associations with cancer? Connections to transcriptional regulation? And finally… Form a hypothesis to pursue as a research oncologist. Dan ended the session with three risks and challenges he feels AI will have in the life sciences 1. Trust - Verification & Validation 2. Keeping Private Data Private (which contradicts federated learning) 3. Most data is terrible, so the results will have issues too. What a stimulating discussion to kick off the next three days at BIO IT. Excited to dive deeper into the innovation in hardware and bioinformatics * finally * being built for life sciences. 

43

5 Kommentare

🌟 Recap of another unforgettable night with the Munich Lab Automation Community! 🌟 What do you get when you gather a bunch of lab automation enthusiasts in one room, sprinkle in some Opentrons magic, and top it off with a game involving matching outfits? You get an evening full of chitchat (watch video below) laughter, learning, and some very questionable fashion choices! 👕🩱👖🧢 This week, we hosted an epic meetup for all Southern Bavarians (& very few aliens) passionate about lab automation. The goal? Chat, network, and geek out over tech! But before we dove into the serious stuff (a.k.a. the future of automation), we decided to break the ice with a little game: form a team of 5 people based on who’s wearing similar-colored clothes. Easy, right? Well… not quite. The winners? The well-coordinated “Blue Chips,” strutting their suave blue shirts. And the runners-up? Let’s just say they embraced diversity. A splash of green here, a pop of green there… their wardrobe choices were anything but cohesive. So, we’ve lovingly dubbed them “The Green Confusion.” Photos? Next week! Stay tuned for the grand reveal of these fashion-forward champions! 📸 🥇 After the game, thanks to Krizia Gallone‘s magic attention tricks, we finally managed to wrangle everyone’s attention. Seriously, getting everyone to stop talking took more effort than programming a liquid handler. Once we had the room’s focus, we launched into two brilliant talks: 🔬 Andreas Blaschke, fresh from his Master’s defense, presented his thesis—which, to be honest, looked suspiciously like a PhD dissertation to all of us. Nice try, Andreas! 👏 🤖 Then, Dan Lord and Elyor Kodirov from Opentrons Labworks Inc. wowed the crowd with their AI-powered and open-source automation platform. And as if that wasn’t enough, they brought their superstar: The Flex! Participants got to personally program the Flex, and yes, it was every bit as amazing as it sounds. Even the AI tools were on offer for a test drive—talk about hands-on learning! 🧠🤖 Meanwhile, Martina Haack, one of our host’s lab heroes, gave us a live demo of her beloved Beckman-i7 liquid handler. Now, Martina loves her i7 deeply, but after spending one night with the Flex, let’s just say her loyalty became somewhat… open & trons & flex_ible and is now under review. 💔❤️‍🩹❓ A massive shoutout to Dania Awad for hosting us and ensuring we were thoroughly spoiled with food and drinks (generously provided by Opentrons—thanks a ton!). The vibe was incredible, and since some of the drinks were not entirely alcohol-free (what a surprise, Bavarians) we’re still not fully sure how some of us made it home safely. 🍻🚶‍♂️ Helge S. Stein 🙏🏻 for babysitting the Flex for 2 weeks. We’ll be meeting again in Jan or Feb—date to be confirmed. Want to make sure you don’t miss out on these fun-filled evenings? Drop me or any of my lovely co-organizers a message. Until next time! And don’t forget—those photos are coming next week! 👀 #labautomation

120

13 Kommentare

Automating the workflows of #chiral separations, and, in fact, the whole #purification workflow with a simple to use set of #Mgears tools, from the #Mnova platform by Mestrelab Research S.L. is a utility that can significantly help to accelerate #drugdiscovery and #drugdevelopment in the #biopharma industry If you are working on #chromatography , this tools can save you a lot of time and speed up your research Do get in touch with Mestrelab Research S.L. to check it out !

16

From ideation to user testing, large language models are allowing companies to explore more ideas and iterate faster. Researchers observed how GenAI can be a catalyst for transforming traditional innovation workflows. The research presents three ways companies can navigate the integration of AI technologies to increase the productivity of their innovation teams: 1. Enhancing Creativity and Design Workflows 2. GenAI for Customer Insights and Concept Validation 3. LLMs as Natural Language Interfaces to Complex Design Tools Beyond the hype, generative AI can bring tangible benefits to companies’ innovation and development processes. https://lnkd.in/ey2VZD66 #ai #productdevelopment

3

3 Kommentare

Techbio Unicorn Owkin Unveils AI-Driven Oncology and Immunology Pipeline : 4 early-stage de novo drug discovery programs and 1 patent-protected in-licensed drug asset ! 🤖𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 Owkin's pipeline leverages several internal AI engines and multimodal patient data from 61 research centers. With a team of 110 data scientists, Owkin uses spatial multiomics data via MOSAIC, the world's largest dataset in oncology, to understand the tumor microenvironment. This expertise positions Owkin to tackle challenges in precision medicine. 🧬𝐀𝐈 𝐄𝐧𝐠𝐢𝐧𝐞𝐬 𝐒𝐞𝐥𝐞𝐜𝐭 𝐎𝐊𝐍𝟒𝟑𝟗𝟓 𝐟𝐨𝐫 𝐢𝐧𝐥𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 Owkin's biomarker engine created detailed EP2/EP4 signatures using multimodal patient data, identifying actionable biomarkers. The AI drug positioning engine screened over 30 cancer indications for OKN4395, identifying the most promising therapeutic combinations for clinical trial 👩‍⚕️𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐎𝐊𝐍𝟒𝟑𝟗𝟓 Owkin plans to use its clinical trial optimization solutions to bring OKN4395 to the patients most likely to benefit from this innovative therapeutic. By utilizing its unique AI-driven pipeline, Owkin aims to enhance precision medicine in oncology and immunology.success.

72

5 Kommentare

Where will AI take clinical development and our ability to treat disease more effectively and efficiently? Google's #DeepMind has just released #AlphaFold3, an AI model that can predict interactions between and among proteins, DNA, RNA, and other molecules with remarkable accuracy. This breakthrough in technology has the potential to revolutionize drug design and the ability to target diseases. DeepMind's updated diffusion-based architecture allows for high-accuracy predictions of biomolecular structures involving proteins, nucleic acids, small molecules, ions, and modified residues, as well as protein-ligand, protein-nucleic acid, and antibody-antigen interactions. #clinicalresearch #FDA #biotech #pharma

1

Who wouldn't want to be the Warren Buffet of #innovations in #biotech, #longevity, #health, #pharma, or medtech #AI? To my best knowledge, there is no such outstanding shining light. Nevertheless, today (not for the first time) I asked myself which #invention platforms or #innovation funding systems are the most successful?   ⁉Who is able to identify the new scientific findings that can really be put into practice and commercialized? And who will succeed in this transfer with a constant and reliably high success rate?   ➡After all, every OECD nation has innovation programs and in Europe the European Union is invested additionally with enormous billions. The reason for my question is that “GSK becomes Flagship Pioneering's latest partner in $7B biobucks respiratory, immunology pact.” Fierce Biotech reports:   “The British drugmaker and the venture creation firm will put a combined $150 million upfront towards a respiratory and immunology-focused research project, which will involve Flagship’s portfolio of over 40 biopharma companies. The goal is to identity up to 10 novel medicines and vaccines, for which GSK will have an exclusive option to take forward for further clinical development…   ⁉Flagship and its biotechs have been on a roll when it comes to signing up major players in the #pharma and #medtech arenas. Last year, Pfizer and Flagship each put down $50 million to build a new pipeline of 10 programs, with the first target being unveiled last month in the red-hot R&D space of obesity.   Obesity was also at the heart of a $600 million biobucks pact signed by Novo Nordisk and Flagship-founded Metaphore Biotechnologies in May…   Earlier this month, Flagship announced a fresh $2.6 billion for its eighth venture fund, with a further $1 billion coming from an array of side funds. At the time, the firm pointed to partnerships with the likes of Pfizer, Thermo Fisher and Samsung…[1]“   ✅#My2_cents   That is pretty impressive. I allowed myself the "pleasure" of using ChatGPT to create a summary of the Pioneer webpage that describes its innovation and pioneering processes[2]. Remarkably, ChatGPT was not able to produce anything useful. Why is that?   ➡I think ChatGPT didn't recognize the essence of the organization.   ➡If you have a mediocre innovation system, you will more often identify only mediocre, less successful ideas.   ➡In my experience, mediocre innovation systems often have mediocre KPIs, which let those who are in charge get away with a mediocre performance.   ➡With organizations like Flagship‘s, there are probably no compromises. At least that's what it looks like to me from the outside. Of the annual pipeline, only about ten percent see the light of day in the end, because the organization has consistently screened out beforehand. This is certainly not the only success factor. But compared to public funding, bold investments into early selection seems to be a major differentiator.   🆔References check my 1st comment   20240729—11733

41

16 Kommentare

Functional characterization of your cell therapy products to facilitate better prediction of clinical outcome and biomarkers - only on the #Beacon #brukercellularanalysis

15

#ASCO2024 is now over, but the French #TransMet study was one of the highlights of the meeting in #digestive #oncology : #liver #transplantation could be a game-changing practice in #CRCm patients with unresectable liver mets. The extent to which lifelong #immunosuppressive drugs will impact on disease #recurrence in the long term remains to be fully elucidated, but the #TransMet efficacy data with a 5-year OS of 73% (vs. 9% for chemo alone) is a complete blow!

14

"The hype will play out in the long term," James Fraser said. "The hard part of drug discovery (is) it's a pretty long business. You can't take the wet lab part out of it yet. Stuff needs to play out in the clinic." Ron Leuty takes an in-depth look at Profluent and how #AI has become a force in drug development (biologics & small molecule). We are seeing this play out in applications to the QB3 mentoring program. It is striking how many new companies are touting that their use of AI/ML provides a competitive advantage. It's almost more remarkable if a drug discovery company is NOT using AI. And it is very hard to judge the longer-term commercial prospects of a new company whose approach relies on AI/ML. Obviously the quality of the data the models are using is paramount. Anyone with thoughts about how to assess these companies, please weigh in! https://lnkd.in/gaVr3CPj

18

👯‍♀️ The digital twin market is projected to reach $287.2 billion by 2032, growing at a 37.7% CAGR. Focusing particularly on the healthcare sector, digital twins are poised to transform patient care by offering real-time simulations of human body functions, enabling personalised treatments and predictive diagnostics. Hospitals will be able to use this technology to enhance operational efficiency, cutting costs while improving patient outcomes. With advancements in AI and machine learning, the adoption of digital twins in healthcare is growing rapidly, allowing for more accurate treatment models and streamlined medical processes. This shift is driving significant growth in the digital twin market, particularly within healthcare systems.

15